What's new
Fantasy Football - Footballguys Forums

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Stock Thread (15 Viewers)

I’m showing a 5.90 ask price currently, would that be our hopeful cydy open? 

 
Last edited by a moderator:
1.88% isn't old man dividend plays.  Todem's list is full of stocks that pay better than that.
Month-end ten largest holdings
as of 05/31/2020

Rank/holdings

1     Walmart Inc.

2     Microsoft Corp.

3     Johnson & Johnson

4     Visa Inc.

5     UnitedHealth Group Inc

6     Procter & Gamble Co.

7     Home Depot Inc.

8     Walt Disney Co.

9     PepsiCo Inc. 

10    Comcast Corp.

OLD MAN DIVIDEND STONKS 

 
Talking about CYDY share price if the Covid results flop and talking about HIV and Cancer are two different conversations.

If Covid flops the share price is gonna tank hard 

Frankly I think we all missed our golden opportunity to sell at 10 and many of us would have if not for that unfortunate short attack.
There was a lot of "not selling" when we were in the 9s. With many not wanting a buy out a fair bit higher than that.

 
Just curious.  If you or a loved one contracted Covid-19 and had the ability for any treatment option which one would you chose?  Knowing what you know would it be Leronlimab or something else?

 
I got in late on CYDY.  I wish I had the ability to add to my position and knock down the cost basis, but its likely another week before I get the cash in the account and have the ability to do something.  So, excuse me if I am hoping for one more week of lower share prices before the trial results take this thing up.  🤞

I've had one day of growth and all red since then.  Its frustrating, but I do believe in what they are trying to accomplish.  My current cost basis is $6.87 and I think that could be a bargain with some real news and positivity.  Hoping I can get that down below 6 before that happens.

 
It goes up.

it goes down.

wont matter when the data comes out one way or the other.
What was the total enrollment for the severe/critical? Anyone can find it? I found articles from May stating 390 in collaboration with Novant, but no press release on their site confirming enrollment fulfilled, only for the 75 mile/moderate.

 
KGB said:
Been Gone 10 years or so.  So I missed the CYDY fun.  Havnt been doing much stocks but...

Old position im down in CRON.  Like the day after I bought some company invested 12 billion in them.  Tripled up, but I was hanging on for the grandslam.  still holding 250 shares at $7.94.

Just purchased...

CHWY - I just believe in the company and think maybe amazon buys them someday.  250 shares @ $45.80

BRPHF - flyer 4000 shares @ 1.27

in GE 500 shares @ $6.86

 
Last edited by a moderator:
Just curious.  If you or a loved one contracted Covid-19 and had the ability for any treatment option which one would you chose?  Knowing what you know would it be Leronlimab or something else?
Honestly--I'd only want to take a treatment if things became moderately to significantly bad.  If things hit those parameters--I'd probably go with Dexamethasone (if things were severe) or leronlimab (if things were moderately bad).   Any mild case I'd probably avoid treatments outside of hydration,  vitamins..etc.  

 
Just curious.  If you or a loved one contracted Covid-19 and had the ability for any treatment option which one would you chose?  Knowing what you know would it be Leronlimab or something else?
If hospitalized that would be my call.

 
Got a non-apple source?
CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, and Scott Kelly, M.D., Chief Medical Officer of CytoDyn, will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Thursday, July 9, 2020 at 1:30 pm ET / 10:30 am PT. The presentation will be approximately 15 minutes followed by a Q&A session of approximately 45 minutes.
 

 
CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, and Scott Kelly, M.D., Chief Medical Officer of CytoDyn, will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Thursday, July 9, 2020 at 1:30 pm ET / 10:30 am PT. The presentation will be approximately 15 minutes followed by a Q&A session of approximately 45 minutes.
 
There's no way they go on camera with terrible results right? 

 
Just curious.  If you or a loved one contracted Covid-19 and had the ability for any treatment option which one would you chose?  Knowing what you know would it be Leronlimab or something else?
Early on dexamethasone, for sure.  If they were getting very sick, then Leronlimab.

 
Got a non-apple source?
Sorry - looked and looked, couldn’t find one

paste:

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, and Scott Kelly, M.D., Chief Medical Officer of CytoDyn, will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Thursday, July 9, 2020 at 1:30 pm ET / 10:30 am PT. The presentation will be approximately 15 minutes followed by a Q&A session of approximately 45 minutes.

 
Last edited by a moderator:
It’s on the PR on their website. At the bottom of the PR it says they’re still enrolling for the severe/critical trial.

The call tomorrow will be fluff and garbage.

https://www.cytodyn.com/newsroom/press-releases/detail/448/cytodyn-to-present-at-wall-street-reporters-livestream

Basically we aren’t close to getting results on the critical/severe patients as the trial is still enrolling? 

CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

 
It’s on the PR on their website. At the bottom of the PR it says they’re still enrolling for the severe/critical trial.

The call tomorrow will be fluff and garbage.

https://www.cytodyn.com/newsroom/press-releases/detail/448/cytodyn-to-present-at-wall-street-reporters-livestream

Basically we aren’t close to getting results on the critical/severe patients as the trial is still enrolling? 

CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
Yah I think just reiterating the same.

 
It’s on the PR on their website. At the bottom of the PR it says they’re still enrolling for the severe/critical trial.

The call tomorrow will be fluff and garbage.

https://www.cytodyn.com/newsroom/press-releases/detail/448/cytodyn-to-present-at-wall-street-reporters-livestream

Basically we aren’t close to getting results on the critical/severe patients as the trial is still enrolling? 

CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
I thought there were rona results coming in July?

 
What was the total enrollment for the severe/critical? Anyone can find it? I found articles from May stating 390 in collaboration with Novant, but no press release on their site confirming enrollment fulfilled, only for the 75 mile/moderate.
Severe/Critical is slated for an enrollment of 390.  Last I heard, they had 127 enrolled.  Initially, they were going to have an interim analysis at 51 patients but the trial started enrolling so quickly that they decided to wait a couple of more weeks to get a larger number of patients.  People are speculating that the interim analysis will have somewhere between 90 and 120 patients.  The mild to moderate trial also enrolled quickly at the end of enrollment so it ended up with 86 or 87 patients.

 
Last edited by a moderator:
As a noob to stocks but as an expert at sniffing out bullsheeeit, CYDY is starting to smell real rotten.
Why? Nothing negative has been released. Shorts are hitting the stock while they can and people are panic selling or having their stops triggered. Most people doing this are a bag of nerves and the shorts know it. Tbh I wish I was in on it. 
 

My only concern is the lack of buyers at 5- but that can be attributed to it not being uplisted imo. 

 
Last edited by a moderator:
Why? Nothing negative has been released. Shorts are hitting the stock while they can and people are panic selling or having their stops triggered. Most people doing this are a bag of nerves and the shorts know it. Tbh I wish I was in on it. 
 

My only concern is the lack of buyers at 5- but that can be attributed to it not being uplisted imo. 
I just see a lot of talking coming from CYDY.  And even the talking isn’t really making a dent in the negative slides. Maybe this is how it works in pharma stocks - as I mentioned I am a noob at this.

But something just isn’t sitting right with me. If they had just stuck with their HIV and cancer angles, I’m boning up all over this thing. But the Covid angle makes them look like they are grasping at straws and the other stuff is being pushed to the wayside by the buying public.

Just feels off to me. That’s all.

 
Last edited by a moderator:
I just see a lot of talking coming from CYDY.  And even the talking isn’t really making a dent in the negative slides. Maybe this is how it works in pharma stocks - as I mentioned I am a noob at this.

But something just isn’t sitting right with me. If they had just stuck with their HIV and cancer angles, I’m boning up all over this thing. But the Covid angle makes them look like they are grasping at straws and the other stuff is being pushed to the wayside by the buying public.

Just feels off to me. That’s all.
Angels? They have drugs in late stages of real treatments

 
I just see a lot of talking coming from CYDY.  And even the talking isn’t really making a dent in the negative slides. Maybe this is how it works in pharma stocks - as I mentioned I am a noob at this.

But something just isn’t sitting right with me. If they had just stuck with their HIV and cancer angles, I’m boning up all over this thing. But the Covid angle makes them look like they are grasping at straws and the other stuff is being pushed to the wayside by the buying public.

Just feels off to me. That’s all.
Imo if you don’t care about covid and are in long  on the hiv and cancer you should be stress free. 

 
I just see a lot of talking coming from CYDY.  And even the talking isn’t really making a dent in the negative slides. Maybe this is how it works in pharma stocks - as I mentioned I am a noob at this.

But something just isn’t sitting right with me. If they had just stuck with their HIV and cancer angles, I’m boning up all over this thing. But the Covid angle makes them look like they are grasping at straws and the other stuff is being pushed to the wayside by the buying public.

Just feels off to me. That’s all.
I’ve read several articles lately comparing Covid and HIV which would lead me to believe an excellent HIV drug may help with Covid.  Doesn't mean CYDY has the right drug or that it even works but it doesn’t seem desperate to me.  One article below:

https://www.nytimes.com/2020/06/26/health/coronavirus-immune-system.html

 
Surprised the CEO  isn’t on Cameo.  

I’ve never seen a drug company CEO wanting the spotlight as much as this guy. 
Scott Kelly, chief medical officer and head of business development, will present as well as NP. One announcement may be that they have received the PDUFA date.

 

Users who are viewing this thread

Back
Top